Mahesh Goel

Mahesh Goel

Auto-generated profile, based on publicly available information

Mahesh Goel

Department of Surgical Oncology Tata Memorial Hospital and Homi Bhabha National Institution Mumbai India

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in HPB
Verified
Journal Article
Closed access
VCVikram A. Chaudhari
Vikram A. Chaudhari
VOVikas Ostwal
Vikas Ostwal
SPShraddha Patkar
Shraddha Patkar
ASArvind Sahu
Arvind Sahu
ATAnup Toshniwal
Anup Toshniwal
MGMahesh Goel
Mahesh Goel

8 July 2011 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
SSShailesh V. Shrikhande
Shailesh V. Shrikhande
SBSavio George Barreto
Savio George Barreto
YBYashodhan D. Bodhankar
Yashodhan D. Bodhankar
KSKunal Suradkar
Kunal Suradkar
GSGuruprasad Shetty
Guruprasad Shetty
PSParul J. Shukla
Parul J. Shukla

25 February 2019 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MGMahesh Goel
Mahesh Goel
KKKrunal Khobragade
Krunal Khobragade
SPShraddha Patkar
Shraddha Patkar
AKAmol Kanetkar
Amol Kanetkar
SKSagar Kurunkar
Sagar Kurunkar

5 February 2016 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MGMahesh Goel
Mahesh Goel
ATAnup Tamhankar
Anup Tamhankar
VRVenkatesh Rangarajan
Venkatesh Rangarajan
SPShraddha Patkar
Shraddha Patkar
MRMukta Ramadwar
Mukta Ramadwar
SSShailesh V. Shrikhande
Shailesh V. Shrikhande

1 October 2016 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
PTPradeep Thapa
Pradeep Thapa
RRRohit Ranade
Rohit Ranade
VOVikas Ostwal
Vikas Ostwal
SSShailesh V. Shrikhande
Shailesh V. Shrikhande
MGMahesh Goel
Mahesh Goel
SBSandip Basu
Sandip Basu
Our data show that high pretherapy F-FDG maximum standardized uptake values were associated with increased chances of treatment refractoriness in GEP-NETs. However, symptomatic improvement was observed in most cases irrespective of grade and F-FDG uptake. High pretherapy F-FDG maximum standardized uptake value in both low-grade and high-grade NET predicted a poor outcome and was associated with disease progression. Introduction of F-FDG-PET/CT parameter as a determinant of response classification increases the percentage of objective scan responders among patients with grades I and II GEP-NETs as F-FDG activity was observed to decrease before SSTR-based imaging and more frequently compared with the latter.

1 March 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
VOVikas Ostwal
Vikas Ostwal
SMSarika Mandavkar
Sarika Mandavkar
PBPrabhat Bhargava
Prabhat Bhargava
SSSujay Srinivas
Sujay Srinivas
AKAkhil Kapoor
Akhil Kapoor
ARAnant Ramaswamy
Anant Ramaswamy
PURPOSE: Human epidermal growth factor receptor 2 (HER2) overexpression is seen in 4%-16% of biliary tract cancers (BTCs). We aimed to evaluate the clinical activity of gemcitabine-cisplatin (GC) plus anti-HER2 antibody trastuzumab as initial treatment in HER2-positive BTCs. METHODS: This study was an investigator-initiated, open-label, single-arm, multi-institutional, phase II trial in adult patients with HER2-positive (defined as immunohistochemistry [IHC] 3+ or IHC 2+ and fluorescent in situ hybridization–positive), treatment-naïve BTCs. The primary end point of the study was 6-month progression-free survival (PFS). Next-generation sequencing was performed on tissue samples to evaluate mutational status. RESULTS: From March 2020 to August 2022, of the 876 screened patients, 118 (13.4%) were found to have HER2-positive status, of whom 90 were enrolled in the study. Most patients had GBC (n = 96; 96%) with two or more sites of metastatic disease (n = 70; 78%). With a median follow-up of 17.3 (95% CI, 15.22 to 19.32) months, 72 patients had disease progression with a median PFS of 7 (95% CI, 6.2 to 7.8) months. The diagnosis to event 6-month PFS rate was 75.6% (95% CI, 66.6 to 84.6). A complete or partial response was seen in 50 (55.5%) patients and 22 (24.4%) patients had stable disease as the best response to treatment, for an overall disease control rate of 80%. The presence of isolated TP53 mutations was associated with inferior PFS compared with other mutations (TERT promoter, HER2, PIK3CA, etc) or no detected mutations (6.51 v 12.02 v 10.58 months; P < .001). CONCLUSION: The combination of GC and trastuzumab achieved its primary end point of improving PFS compared with historical data in the treatment-naïve HER2-positive BTC. Evaluating additional mutations such as TP53 and PIK3CA along with HER2 testing may help to preferentially select patients for anti-HER2 therapy in the future (Clinical Trial Registry India number: CTRI/2019/11/021955).